메뉴 건너뛰기




Volumn 16, Issue 5, 2015, Pages 749-754

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer

Author keywords

Androgen receptor; Castration resistant prostate cancer; Enzalutamide; MDV3100

Indexed keywords

ANTINEOPLASTIC AGENT; ENZALUTAMIDE; PLACEBO; ANDROGEN RECEPTOR ANTAGONIST; PHENYLTHIOHYDANTOIN;

EID: 84924351297     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1016911     Document Type: Review
Times cited : (14)

References (25)
  • 1
    • 84892805731 scopus 로고    scopus 로고
    • Cancer statistics, 2014
    • Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
    • (2014) CA Cancer J Clin , vol.64 , Issue.1 , pp. 9-29
    • Siegel, R.1    Ma, J.2    Zou, Z.3
  • 2
    • 0015370976 scopus 로고
    • Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
    • Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22(4):232-40
    • (1972) CA Cancer J Clin , vol.22 , Issue.4 , pp. 232-240
    • Huggins, C.1    Hodges, C.V.2
  • 3
    • 51449087794 scopus 로고    scopus 로고
    • Targeting the androgen receptor pathway in prostate cancer
    • Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-8
    • (2008) Curr Opin Pharmacol , vol.8 , Issue.4 , pp. 440-448
    • Chen, Y.1    Sawyers, C.L.2    Scher, H.I.3
  • 4
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
    • (2012) N Engl J Med , vol.367 , Issue.13 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 5
    • 84908450155 scopus 로고    scopus 로고
    • Enzalutamide in metastatic prostate cancer before chemotherapy
    • Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
    • (2014) N Engl J Med , vol.371 , Issue.5 , pp. 424-433
    • Beer, T.M.1    Armstrong, A.J.2    Rathkopf, D.E.3
  • 6
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1502-1512
    • Tannock, I.F.1    De Wit, R.2    Berry, W.R.3
  • 7
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 8
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 9
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23
    • (2013) N Engl J Med , vol.369 , Issue.3 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 10
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-t immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
    • (2010) N Engl J Med , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 11
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 12
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
    • (2013) N Engl J Med , vol.368 , Issue.2 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 13
    • 65649090203 scopus 로고    scopus 로고
    • Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    • Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
    • (2009) Science , vol.324 , Issue.5928 , pp. 787-790
    • Tran, C.1    Ouk, S.2    Clegg, N.J.3
  • 14
    • 0031048446 scopus 로고    scopus 로고
    • The antiandrogen withdrawal syndrome in relapsed prostate cancer
    • discussion 24-27
    • Scher HI, Kolvenbag GJ. The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol 1997;31(Suppl 2):3-7.discussion 24-27
    • (1997) Eur Urol , vol.31 , pp. 3-7
    • Scher, H.I.1    Kolvenbag, G.J.2
  • 15
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of mdv3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of mdv3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
    • (2010) Lancet , vol.375 , Issue.9724 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 16
    • 77950574393 scopus 로고    scopus 로고
    • Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (crpc)
    • Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (crpc). J Med Chem 2010;53(7):2779-96
    • (2010) J Med Chem , vol.53 , Issue.7 , pp. 2779-2796
    • Jung, M.E.1    Ouk, S.2    Yoo, D.3
  • 18
    • 84893349290 scopus 로고    scopus 로고
    • Improved outcomes in elderly patients with metastatic castrationresistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase iii affirm trial
    • Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castrationresistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase iii affirm trial. Ann Oncol 2014;25(2):429-34
    • (2014) Ann Oncol , vol.25 , Issue.2 , pp. 429-434
    • Sternberg, C.N.1    De Bono, J.S.2    Chi, K.N.3
  • 19
    • 84907057471 scopus 로고    scopus 로고
    • Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer
    • Antonarakis ES, Lu C, Wang H, et al. Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38
    • (2014) N Engl J Med , vol.371 , Issue.11 , pp. 1028-1038
    • Antonarakis, E.S.1    Lu, C.2    Wang, H.3
  • 20
    • 84882274167 scopus 로고    scopus 로고
    • Nf-kappab2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants
    • Nadiminty N, Tummala R, Liu C, et al. Nf-kappab2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013;12(8):1629-37
    • (2013) Mol Cancer Ther , vol.12 , Issue.8 , pp. 1629-1637
    • Nadiminty, N.1    Tummala, R.2    Liu, C.3
  • 21
    • 48549089747 scopus 로고    scopus 로고
    • Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
    • Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68(13):5469-77
    • (2008) Cancer Res , vol.68 , Issue.13 , pp. 5469-5477
    • Dehm, S.M.1    Schmidt, L.J.2    Heemers, H.V.3
  • 22
    • 58249110391 scopus 로고    scopus 로고
    • Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
    • Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16-22
    • (2009) Cancer Res , vol.69 , Issue.1 , pp. 16-22
    • Hu, R.1    Dunn, T.A.2    Wei, S.3
  • 23
    • 62949147825 scopus 로고    scopus 로고
    • US Food and Drug Administration. European medicines agency. Available from: http://www.ema.europa.eu
    • European Medicines Agency
  • 24
    • 84924364276 scopus 로고    scopus 로고
    • Primary, secondary, and quality-of-life endpoint results from prevail, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mcrpc)
    • abstract 5007
    • Armstrong AJ, Tombal B, Sternberg CN, et al. Primary, secondary, and quality-of-life endpoint results from prevail, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mcrpc). J Clin Oncol 2014;32(5s):abstract 5007
    • (2014) J Clin Oncol , vol.32 , Issue.5 S
    • Armstrong, A.J.1    Tombal, B.2    Sternberg, C.N.3
  • 25
    • 84908575897 scopus 로고    scopus 로고
    • Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 affirm trial
    • Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 affirm trial. Lancet Oncol 2014;15(10):1147-56
    • (2014) Lancet Oncol , vol.15 , Issue.10 , pp. 1147-1156
    • Fizazi, K.1    Scher, H.I.2    Miller, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.